Anti-helicobacter pylori specific antibodies, plasmid vectors and methods
By designing recombinant UreB antigens and screening B lymphocytes using flow cytometry, constructing and purifying monoclonal antibodies, and preparing fluorescent microsphere immunoassay cards, the problems of long cycle, low purity, and large batch-to-batch variability in the preparation of monoclonal antibodies from mouse ascites fluid were solved, achieving high efficiency, accuracy, and simplification in the detection of Helicobacter pylori.
Patent Information
- Application Number
- CN202311739983.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-18
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-12-18
AI Technical Summary
Traditional methods for preparing monoclonal antibodies against Helicobacter pylori UREB protein from mouse ascites fluid are time-consuming, have low purity, and exhibit significant batch-to-batch variability, resulting in poor detection accuracy.
Recombinant UreB antigen was designed, and B lymphocytes that specifically bind to it were screened by flow cytometry. The antibody nucleotide sequence was amplified, a recombinant plasmid was constructed, and a monoclonal antibody was expressed in HEK293 cells. The antibody was purified using Protein A affinity chromatography, and fluorescent microspheres were used to label the antibody to prepare a fluorescent microsphere immunoassay card.
It improves the specificity and sensitivity of Helicobacter pylori detection, simplifies the detection process, reduces batch-to-batch variability, and is suitable for large-scale clinical testing and epidemiological surveys.
Smart Images

Figure REF-OBJ-1789457291007-000001
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology. Specifically, it relates to an anti-Helicobacter pylori specific antibody, a plasmid vector, and a method. Background Technology
[0002] Helicobacter pylori is a Gram-negative spiral-shaped bacterium found on the gastric mucosa. It is 5-50 μm long and thin. This bacterium is not very resistant to the external environment and is sensitive to both dryness and heat. It is easily killed by various commonly used disinfectants. However, Helicobacter pylori lowers the acidity in the stomach, allowing bacteria that cannot normally survive in the stomach to multiply, damaging the gastric mucosa, causing gastric acid to corrode normal tissue, leading to chronic ulcers that are difficult to heal, and increasing the risk of perforation, cell mutation, and cancer. Helicobacter pylori infection is the primary mode of transmission, although its exact route is not fully understood, but the most likely routes are oral-oral and fecal-oral transmission. On October 27, 2017, the World Health Organization included Helicobacter pylori in its list of Group 1 carcinogens for the first time. Therefore, the diagnosis of Helicobacter pylori infection is of great value in the prevention and treatment of gastric ulcers and gastric cancer.
[0003] Currently, the main methods for detecting Helicobacter pylori include breath tests, immunological tests, direct bacterial detection, rapid urease tests, gastric mucosal tissue section staining microscopy, direct gastric mucosal smear staining microscopy, polymerase chain reaction (PCR) tests, C13 and C14 urea breath tests, 15N urinary ammonia excretion tests, and antibody tests. Some of these methods require highly accurate and expensive equipment, such as breath tests and C13 and C14 urea breath tests. Other methods are complex, such as gastric mucosal tissue section staining microscopy, direct gastric mucosal smear staining microscopy, and PCR tests, all of which require gastric mucosal sampling. These methods require specific equipment or procedures, making them extremely inconvenient for most people.
[0004] Immunoassay techniques, such as the ELISA double-antibody sandwich method, monoclonal antibody technology, and solid-phase immunoassay, have proven particularly effective in the rapid diagnosis of Helicobacter pylori. These techniques not only simplify the testing process but also improve the specificity and sensitivity of Helicobacter pylori detection. Among these, Helicobacter pylori monoclonal antibody technology overcomes the limitations of in vitro culture, reduces the need for high-titer immune sera, and allows for serotyping and strain identification, making it suitable for large-scale clinical testing and epidemiological surveys.
[0005] Therefore, the preparation of Helicobacter pylori (HP) UREB protein monoclonal antibodies for specific recognition and detection of HP has become a major method for early diagnosis. The conventional preparation of HP UREB protein monoclonal antibodies involves preparing ascites fluid from a Helicobacter pylori (HP) UREB protein monoclonal cell line in Balb / c mice, and purifying the monoclonal antibody using Protein A affinity chromatography. However, due to the uncertainty of ascites fluid yield per mouse and large individual variability, the obtained anti-HP UREB protein monoclonal antibodies show large batch-to-batch variations, resulting in poor detection accuracy.
[0006] Design objective: To address the shortcomings of traditional mouse ascites preparation for monoclonal antibody production, such as long cycle time, low purity, and large batch-to-batch variability, this study designed and synthesized recombinant UreB antigen and immunized mice with it. Flow cytometry was used to screen for lymphocytes that specifically bind to the recombinant UreB antigen, and the antibody nucleotide sequence was amplified. Monoclonal antibodies were then prepared through transient transfection expression.
[0007] Design scheme: To achieve the above design purpose. This application: (1) After repeatedly immunizing Balb / c mice with recombinant UreB antigen, their spleens were taken, and their splenic lymphocytes were separated using a lymphocyte separation kit. The B lymphocyte suspension was specifically sorted by flow cytometry and collected in a 96-well PCR plate containing appropriate amounts of cell lysis buffer, RNase inhibitor and PCR reaction reagent. A mixture of forward primers was designed for different leader sequences of the variable region of the antibody heavy chain and light chain. The reverse primers were specifically complementary to the constant region of the antibody. The mRNA was reverse transcribed into cDNA. The corresponding antibody variable region nucleotide sequence was cloned by RT-PCR, purified by gel electrophoresis, and sequenced. Finally, the antibody nucleotide sequence that can bind to recombinant UreB antigen was obtained. (2) The heavy chain and light chain sequences were used to construct a complete mouse IgG expression vector and expressed monoclonal antibodies using HEK293 cells. The monoclonal antibodies were purified by Protein A affinity chromatography and fluorescent microspheres were formed. (3) The optimal monoclonal antibody pairing combination was determined by immunofluorescence orthogonal experiment, showing that 3B2 and 4F1 are the best monoclonal antibodies for the detection of Helicobacter pylori. Detailed Implementation
[0008] Although the following embodiments provide a relatively detailed textual description of the design concept of the present invention, these textual descriptions are merely simple textual descriptions of the design concept of the present invention and are not intended to limit the design concept of the present invention. Any combination, addition, or modification that does not exceed the design concept of the present invention falls within the protection scope of the present invention.
[0009] Example 1: Selection of dominant antigenic epitopes in Helicobacter pylori (HP) Using the UreB protein of Helicobacter pylori (HP) as the target antigen, the hydrophilicity and antigenicity of its antigenic epitope sequence were analyzed using the biological software DNAssist 2.0. Sequence comparison results showed that the selected dominant antigenic epitope sequence of the UreB protein had broad spectrum and was a common epitope of all Helicobacter pylori (HP) UreB proteins; furthermore, the UreB protein epitope showed no significant homology with other protein sequences and was found only in the UreB protein sequence of Helicobacter pylori (HP).
[0010] Example 2: Optimization of the nucleotide sequence of recombinant UreB protein To improve the expression level of recombinant UreB protein in *E. coli*, the amino acid sequence encoding the recombinant UreB protein was converted into the corresponding nucleotide sequence according to the codons preferred by *E. coli*, while maintaining the amino acid sequence unchanged. Nucleotides corresponding to the BamHI and EcoRI restriction enzyme sites were then added upstream and downstream of the protein, respectively. The resulting protein was synthesized by General Biosystems Anhui Co., Ltd. The synthesized target gene was cloned into the pMD25-T vector (Takara Bio Engineering Dalian Co., Ltd.).
[0011] Example 3: Construction of a recombinant UreB protein expression vector The pMD25-T vector and PET-32a(+) vector (Novagen, Germany) containing the target gene were double-digested at 37°C for 12 hours with restriction endonucleases BamHI and EcoRI (Takara Bio Engineering, Dalian Co., Ltd.). The digestion products were subjected to 1% agarose gel electrophoresis, and the target gene and PET-32a(+) vector were recovered by gel extraction (the gel extraction kits used in this invention were all from Aisjin Biotechnology, Hangzhou Co., Ltd.). The recovered target gene and PET-32a(+) vector were ligated at a certain ratio at 4℃ for 12 hours using T4 ligase (Takara Bio Engineering Dalian Co., Ltd.). The ligation product was then transformed into DH5α competent cells (Hangzhou Xianzhi Biotechnology Co., Ltd.) and plated on LB agar containing ampicillin resistance (50 μg / mL). After incubation at 37℃ for 12 hours, single clones were picked from the agar and transferred to LB liquid medium containing ampicillin resistance (50 μg / mL). After incubation at 37℃ for 12 hours, plasmids were extracted using a plasmid purification kit (all plasmid extraction kits used in this invention were from Aisjin Biotechnology Hangzhou Co., Ltd.). The correct recombinant expression vector was obtained after double digestion with BamHI and EcoRI.
[0012] Example 4: Construction of a recombinant UreB protein antigen expression strain The constructed recombinant UreB protein expression vector was transformed into E. coli ER2566 competent cells and plated on LB agar plates containing ampicillin-resistant (50 μg / mL) medium, and cultured overnight at 37°C. The next day, single clones from the plates were picked and cultured in LB liquid medium containing ampicillin-resistant (50 μg / mL) medium at 37°C for 8 hours using a shaker. Then, isopropyl thio-β-D-galactopyranoside (final concentration 1.0 mmol / L) was added to induce expression for 4 hours, followed by protein electrophoresis. 9% polyacrylamide gel electrophoresis results showed successful expression of the recombinant UreB protein, yielding a recombinant UreB protein antigen-expressing strain.
[0013] Example 5: Purification of recombinant UreB protein The recombinant UreB protein-expressing strain was inoculated into LB liquid medium, and ampicillin was added to a final concentration of 50 μg / mL. After incubation at 37°C in a shaker for 8 hours, the strain was diluted 1:100 with LB liquid medium containing 50 μg / mL ampicillin and aliquoted into bacterial culture flasks. The flasks were then incubated at 37°C in a shaker until OD600 = 0.8. Isopropyl thio-β-D-galactopyranoside was added to a final concentration of 1.0 mmol / L, and induction was continued for 4 hours. After centrifugation to collect the bacterial cells, the cells were lysed by sonication at 4°C. The supernatant was then passed through a nickel-agarose affinity chromatography column, and the purified recombinant UreB protein was obtained after washing and elution.
[0014] Example 6: Preparation of anti-Helicobacter pylori monoclonal antibody Recombinant UreB antigen immunogen was subcutaneously injected at multiple sites on the frontal and dorsal sides of 4-6 week old Balb / c female mice. For the first immunization, 100 μg of recombinant UreB antigen was emulsified with Freund's complete adjuvant, 400 μl per mouse. A second booster immunization was performed 20 days later, using 80 μg of recombinant UreB antigen emulsified with Freund's incomplete adjuvant, 400 μl per mouse. A third booster immunization was performed 15 days later, using the same method as the second booster. Twenty days later, 120 μg of recombinant UreB antigen was injected intraperitoneally, and the mice were sacrificed 72 hours later. The spleen was removed, and splenic lymphocytes were isolated using a mouse lymphocyte separation kit (Tianjin Haoyang Biological Products Technology Co., Ltd.). Target B lymphocytes were stained with a fluorescently labeled probe prepared with recombinant UreB antigen, and single B cells expressing specific antibodies were isolated using flow cytometry fluorescence sorting. mRNA was extracted from single B cells and cDNA was synthesized by RT-PCR. Using cDNA as a template, universal degenerate primers for the variable region of mouse antibodies were used to amplify the nucleotide sequences encoding the variable regions of the antibody light and heavy chains. These sequences were then ligated to the constant regions and inserted into the pcDNA3.1(+) vector to construct recombinant plasmids expressing the specific antibody light and heavy chains. The light chain plasmid and heavy chain plasmid of the same antibody were mixed at a 1:1 mass ratio and transfected into HEK293F cells for culture. After 7 days of incubation in a shaker at 37°C and 5% CO2 at 120 rpm, the cell culture medium was collected and purified using Protein A affinity chromatography to obtain monoclonal antibodies. Purity was detected by Coomassie brilliant blue staining after 10% SDS-PAGE electrophoresis. The purified monoclonal antibodies were also screened by ELISA using the following steps: Coating: Dilute the recombinant UreB antigen with coating buffer to a final concentration of 1 μg / mL, add 100 μL / well to the microplate (Shenzhen Jincanhua Industrial Co., Ltd.), incubate overnight at 4°C, and then wash once with washing buffer using a DEM-3 plate washer (Sun Yat-sen University Da An Gene Co., Ltd.). Blocking: Add 200 μL of blocking solution to each well, block at 37°C for 2 hours, and wash once with washing solution using a plate washer; Add 100 μL of purified monoclonal antibody and control serum diluted at a certain ratio to the UreB antigen-coated wells, incubate at 37°C for 1 h, and wash 3 times with washing buffer using a plate washer. Add enzyme-labeled antibody: Coat wells with UreB antigen, add 100 μL / well of freshly diluted HRP-labeled secondary antibody, incubate at 37°C for 30 minutes, and then wash 4 times with washing buffer using a plate washer. Add colorimetric reagents: Add 50 μL of colorimetric reagent A and 50 μL of colorimetric reagent B to each well, and develop the color at 37°C in the dark for 10 minutes. Termination of reaction: Add 50 μL of stop solution per well; Results Interpretation: Absorbance values were read at 450 nm using a microplate reader after zeroing the blank wells. Immune mouse serum was used as a positive control. Results showed that five positive clones had high absorbance values in the UreB antigen wells. Sequencing yielded five sequences: 1A8, 3B2, 4F1, 5D3, and 5D9.
[0015] The relevant solution formulations are as follows: Coating solution: Na2CO3 1.5g, NaHCO3 2.9g, add ddH2O to make up to 1000mL (pH 9.6).
[0016] Blocking solution: Na2HPO4·12H2O 2.68g, NaH2PO4·2H2O 0.39g, NaCl 8.5g, 20g bovine serum albumin, add ddH2O to bring the volume to 1000mL (pH 7.4).
[0017] Washing solution: Na2HPO4·12H2O 2.68g, NaH2PO4·2H2O 0.39g, NaCl 8.5g, Tween-20 0.5mL, add ddH2O to make up to 1000mL (pH 7.4).
[0018] Colorimetric solution A: Dissolve 200 mg TMB in 100 mL of anhydrous ethanol, and add ddH2O to bring the volume to 1000 mL.
[0019] Colorimetric solution B: 2.1g citric acid, 71g Na2HPO4·12H2O, add ddH2O to make up to 1000mL.
[0020] When using: 1 mL of colorimetric solution A + 1 mL of colorimetric solution B + 0.4 μL of 30% H2O2 Stop solution: 2M H2SO4, 21.7mL concentrated H2SO4, add ddH2O to make up to 1000mL.
[0021] Example 7: Preparation of fluorescent microspheres labeled with anti-Helicobacter pylori monoclonal antibody Fluorescent microspheres (Bangslab, Dragongreen) with a diameter of 190 nm were selected. The concentration of the microspheres was adjusted to 1% using 0.05 M pH 4.5 MES buffer. Anti-Helicobacter pylori monoclonal antibody was then covalently coupled to the fluorescent microspheres using carbodiimide (EDC) and succinimide (NHS) at a concentration of 0.2 mg / ml. The prepared fluorescent microspheres were sprayed onto the fluorescent microsphere pads at a rate of 4 μl / cm using a quantitative spraying device, and then vacuum-dried at 25 °C for 1–2 h before being stored in a dry environment for later use.
[0022] Example 8: Preparation of nitrocellulose membrane (NC membrane) Anti-Helicobacter pylori monoclonal antibodies (1A8, 3B2, 4F1, 5D3, 5D9) were adjusted to a concentration of 0.4 mg / mL using 0.01 M pH 7.4 PBS (phosphate buffer, containing 5% sucrose and 0.05% Tween-20). The resulting solutions were then sprayed onto the NC membrane to form detection lines (T lines). Goat anti-mouse antibodies were adjusted to a concentration of 0.5 mg / mL using 0.01 M pH 7.4 PBS (phosphate buffer, containing 5% sucrose and 0.05% Tween-20). This solution was then sprayed onto the NC membrane to form control zones (C lines). The spray volume for both zones was 1 μL / cm, with a 5 mm gap between the two zones. The control zone was 2 mm from one end of the NC membrane. After drying at 37°C overnight, the membranes were stored at room temperature in a dry environment for later use.
[0023] Example 9: Preparation of Fluorescent Microsphere Immunoassay Card Assemble the test strip: On the PVC base plate, overlap and paste the following in sequence: (1) Spray anti-Helicobacter pylori monoclonal antibody (1A8, 3B2, 4F1, 5D3, 5D9) as the detection area and goat anti-mouse IgG as the quality control area NC membrane; (2) Spray fluorescent microsphere pad with fluorescent microsphere labeled anti-Helicobacter pylori monoclonal antibody (1A8, 3B2, 4F1, 5D3, 5D9); (3) Filter paper and sample pad, the sample pad is a glass fiber membrane treated with 2% Tween-20; (4) Absorbent paper, after assembly, cut to a width of 4mm, attach the reagent card shell and press it tightly to obtain the fluorescent microsphere immunochromatographic detection card.
[0024] Example 10: Screening of paired monoclonal antibodies Sterile swabs were inserted into Helicobacter pylori-positive and Helicobacter pylori-negative fecal samples, respectively, and then immediately immersed in 1 mL of diluent. The swabs were rotated at least 10 times until the samples were completely dissolved in the diluent. 100 μL of sample was loaded per well. After incubation at room temperature for 15 min, the T and C line signals on the NC membrane were read using a fluorescence analyzer (BaseBio Biotechnology Co., Ltd.), and the measured value T / (T+C) was calculated. See Table 1 for details.
[0025]
[0026] The table above shows that the optimal antibody pairing for Helicobacter pylori detection is the combination of 3B2 monoclonal antibody coating and 4F1 monoclonal antibody-labeled fluorescent microspheres.
Claims
1. A specific antibody 3B2 against Helicobacter pylori, comprising a light chain and a heavy chain, characterized in that: The amino acid sequence of the variable region of the light chain is shown in SEQ ID NO.1; The amino acid sequence of the variable region of the heavy chain is shown in SEQ ID NO.
2.
2. A plasmid vector combination, characterized in that: This plasmid vector combination contains nucleotide sequences as shown in SEQ ID NO.5 and SEQ ID NO.
6.
3. A specific antibody against Helicobacter pylori, 4F1, comprising a light chain and a heavy chain, characterized in that: The amino acid sequence of the variable region of the light chain is shown in SEQ ID NO.3; The amino acid sequence of the variable region of the heavy chain is shown in SEQ ID NO.
4.
4. A plasmid vector combination, characterized in that: This plasmid vector combination contains nucleotide sequences as shown in SEQ ID NO.7 and SEQ ID NO.
8.
5. A method for preparing an anti-Helicobacter pylori specific antibody as described in any one of claims 1 or 3, comprising the following steps: a) By PCR, the nucleotide sequences encoding the variable region of the light chain and the variable region of the heavy chain were bridged with the nucleotide sequences encoding the constant region of the mouse IgG light chain and the constant region of the heavy chain, respectively, and then digested with enzymes and ligated into plasmid vectors to construct eukaryotic cell expression vectors. b) Transfect the eukaryotic expression vector from step a) into HEK293F cells to express the anti-Helicobacter pylori monoclonal antibody; c) Purify monoclonal antibodies; The nucleotide sequence encoding the variable region of the light chain is shown in SEQ ID NO.
5. The nucleotide sequence of the variable region encoding the heavy chain is shown in SEQ ID NO. 6; or, The nucleotide sequence encoding the variable region of the light chain is shown in SEQ ID NO.
7. The nucleotide sequence of the variable region encoding the heavy chain is shown in SEQ ID NO.8.
Citation Information
Patent Citations
Helicobacter pylori multivalent epitope vaccine and preparation method thereof
CN105169381A
Helicobacter pylori vaccine recombinant protein antigen UreB-s as well as preparation method and application thereof
CN116286757A
